Statement: the primary trial at least 8 different types of cardiac related adverse events.
Primary_evidence: Adverse Events 1:   Total: 20/52 (38.46%)   Anaemia 0/52 (0.00%)   Pancytopenia 1/52 (1.92%)   Acute myocardial infarction 0/52 (0.00%)   Atrial fibrillation 0/52 (0.00%)   Cardiac failure 1/52 (1.92%)   Cardiogenic shock 1/52 (1.92%)   Palpitations 0/52 (0.00%)   Pericardial effusion 0/52 (0.00%)   Right ventricular failure 1/52 (1.92%)   Abdominal pain 0/52 (0.00%)   Ascites 3/52 (5.77%) Adverse Events 2:   Total: 25/49 (51.02%)   Anaemia 2/49 (4.08%)   Pancytopenia 0/49 (0.00%)   Acute myocardial infarction 1/49 (2.04%)   Atrial fibrillation 1/49 (2.04%)   Cardiac failure 0/49 (0.00%)   Cardiogenic shock 0/49 (0.00%)   Palpitations 1/49 (2.04%)   Pericardial effusion 4/49 (8.16%)   Right ventricular failure 0/49 (0.00%)   Abdominal pain 1/49 (2.04%)   Ascites 0/49 (0.00%)